IRCT20200105046010N56招募中未知
In- Vivo Bioequivalence study of Dasatinib tablet 140 mg Nano Alvand Pharma. with brand drug (SPRYCEL® 140 mg, Rosche, Switzerland) in Iranian healthy volunteers.
anoalvand Pharmaceutical Co0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •General health
- •Body mass index between18-28
- •Informed consent
- •Informed consentBeing at the age of 18-60 years old
排除标准
- •A history of cardiovascular disease
- •A history of liver & kidney disease
- •Alcohol & Drug addiction
- •Hypersensitivity to the drug
研究者
相似试验
招募中
不适用
In-vivo Bioequivalence Test of Dasatonib tablet 100 mg Abidi Pharma with brand drug (SPRYCEL® 100 mg FC Tab, Bristol-Myers Squibb, UK)Bio equivalence test.IRCT20200105046010N66Abidi Pharmaceutical Company24
招募中
Unknown
Bioequivalence study of Dasatinib 100 mg tabletThis study is performed on healthy volunteers..IRCT20200105046010N81Actero Pharma Company24
招募中
不适用
Bioequivalence study of Dasatinib 50 mg tabletIRCT20200623047902N22Zistdaru danesh Co.48
尚未招募
不适用
Study to compare efficacy & safety of Dasatinib with respect to Imatinib in newly diagnosed cases of chronic phase of chronic myeloid leukemia in terms of early response assessment at three months of therapyCTRI/2022/03/041208aiims rishikesh
招募中
不适用
In-vivo Bioequivalence study of Tadalafil tablet with brand drugs (CIALIS Lilly USA)IRCT20200105046010N39Mofid Pharmaceutical Co.24